MP36-20 INTRAMUSCULAR TESTOSTERONE CYPIONATE VS SUBCUTANEOUS TESTOSTERONE ENANTHATE: COMPARING THE OUTCOMES IN HYPOGONADAL MEN

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II (MP36)1 Sep 2021MP36-20 INTRAMUSCULAR TESTOSTERONE CYPIONATE VS SUBCUTANEOUS TESTOSTERONE ENANTHATE: COMPARING THE OUTCOMES IN HYPOGONADAL MEN Edward Choi, Perry Xu, Farouk El-Khatib, Faysal Yafi, and Parviz Kavoussi Edward ChoiEdward Choi More articles by this author , Perry XuPerry Xu More articles by this author , Farouk El-KhatibFarouk El-Khatib More articles by this author , Faysal YafiFaysal Yafi More articles by this author , and Parviz KavoussiParviz Kavoussi More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002045.20AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Intramuscular testosterone cypionate (IM-TC) is the conventional treatment option for hypogonadal men with baseline serum total testosterone (TT) less than 300 ng/dL; however, significant peaks in testosterone cause adverse effects including polycythemia and rise in estradiol (E2). Subcutaneous testosterone enanthate-autoinjectors (SCTE-AI) were designed with a lower testosterone peak-to-trough ratio of 1.8. This dual-institutional study compared the TT, hematocrit (HCT), E2, and prostate-specific antigen (PSA) response to treatment with IM-TC versus SCTE-AI. METHODS: 263 hypogonadal men were treated with testosterone replacement therapy (TRT) via IM-TC 100 mg weekly or SCTE-AI 100 mg weekly. TT, HCT, E2, and PSA levels were obtained at baseline and 6- to 12-weeks post-treatment. Significant differences in baseline and post-treatment levels were identified by univariate analysis. Linear regression models determined whether treatment modality was independently associated with post-TRT levels of TT, HCT, E2, and PSA. RESULTS: Patients treated with SCTE-AI were significantly younger, had higher baseline TT levels, and lower baseline E2 levels. Post-TRT, both cohorts had significant increases in trough TT compared to their respective baseline levels (IM-TC: 313.6 ng/dL to 536.4 ng/dL, p<0.001; SCTE-AI: 249.6 ng/dL to 540.4 ng/dL, p<0.001). When comparing between cohorts, the SCTE-AI cohort group had significantly lower HCT and E2, while TT and PSA levels were not significantly different between the treatment arms. After adjusting for significant differences with linear regression, SCTE-AI was associated with a 14% greater increase in trough TT levels compared to IM-TC (p=0.027). Furthermore, SCTE-AI was independently associated with 41% and 27% lower post-therapy HCT (p<0.001) and E2 (p<0.001) levels, respectively, when compared to IM-TC (Table 2b-c). Neither TRT modality was associated with significant post-therapy elevation of PSA (p=0.691). CONCLUSIONS: While IM-TC and SCTE-AI provide a significant increase in TT levels, SCTE-AI is associated with lower levels of post-therapy HCT and E2 compared to IM-TC after adjusting for significant covariates. SCTE-AI is an effective testosterone delivery system with a potentially preferable safety profile over IM-TC. Source of Funding: n/a © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e643-e644 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Edward Choi More articles by this author Perry Xu More articles by this author Farouk El-Khatib More articles by this author Faysal Yafi More articles by this author Parviz Kavoussi More articles by this author Expand All Advertisement Loading ...